Axura

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
26-02-2024
Karakteristik produk Karakteristik produk (SPC)
26-02-2024

Bahan aktif:

memantine hydrochloride

Tersedia dari:

Merz Pharmaceuticals GmbH

Kode ATC:

N06DX01

INN (Nama Internasional):

memantine

Kelompok Terapi:

Other anti-dementia drugs

Area terapi:

Alzheimer Disease

Indikasi Terapi:

Treatment of patients with moderate to severe Alzheimer's disease.

Ringkasan produk:

Revision: 27

Status otorisasi:

Authorised

Tanggal Otorisasi:

2002-05-17

Selebaran informasi

                                52
B. PACKAGE LEAFLET
53
PACKAGE LEAFLET: INFORMATION FOR THE USER
AXURA 10 MG FILM-COATED TABLETS
Memantine hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Axura is and what it is used for
2.
What you need to know before you take Axura
3.
How to take Axura
4.
Possible side effects
5.
How to store Axura
6.
Content of the pack and other information
1.
WHAT AXURA IS AND WHAT IT IS USED FOR
HOW DOES AXURA WORK
Axura contains the active substance memantine hydrochloride.
Axura belongs to a group of medicines known as anti-dementia
medicines.
Memory loss in Alzheimer’s disease is due to a disturbance of
message signals in the brain. The brain
contains so-called N-methyl-D-aspartate (NMDA)-receptors that are
involved in transmitting nerve
signals important in learning and memory. Axura belongs to a group of
medicines called NMDA-
receptor antagonists. Axura acts on these NMDA-receptors improving the
transmission of nerve
signals and the memory.
WHAT IS AXURA USED FOR
Axura is used for the treatment of patients with moderate to severe
Alzheimer’s disease.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE AXURA
DO NOT TAKE AXURA
-
if you are allergic (hypersensitive) to memantine hydrochloride or any
of the other ingredients
of Axura tablets (listed in section 6).
WARNING AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Axura
-
if you have a history of epileptic seizures
-
if you have recently experienced a myocardial infarction (heart
attack), or if you are suffering
from conges
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Axura 10 mg film-coated tablets
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
Axura 20 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Axura 10 mg film-coated tablets
Each film-coated tablet contains 10 mg of memantine hydrochloride
equivalent to 8.31 mg memantine.
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
Each filmcoated tablet contains 5 mg of memantine hydrochloride
equivalent to 4.15 mg memantine.
Each film-coated tablet contains 10 mg of memantine hydrochloride
equivalent to 8.31 mg memantine.
Each film-coated tablet contains 15 mg of memantine hydrochloride
equivalent to 12.46 mg memantine.
Each film-coated tablet contains 20 mg of memantine hydrochloride
equivalent to 16.62 mg memantine.
Axura 20 mg film-coated tablets
Each film-coated tablet contains 20 mg of memantine hydrochloride
equivalent to 16.62 mg memantine.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Axura 10 mg film-coated tablets
Pale yellow to yellow, oval shaped film-coated tablet with breaking
line and engravings "1-0" on one
side and "M M" on the other side.
The tablet can be divided into equal doses.
Axura 5 mg+10 mg+15 mg+20 mg film-coated tablets
The 5 mg film-coated tablets are white to off-white, oval-oblong
film-coated tablets with imprint ‘5’ on
one side and imprint ‘MEM’ on the other side.
The 10 mg film-coated tablets are pale yellow to yellow, oval shaped
film-coated tablet with breaking
line and engravings "1-0" on one side and "M M" on the other side. The
tablet can be divided into
equal doses.
The 15 mg film-coated tablets are orange to grey-orange, oval-oblong
film-coated tablets with imprint
‘15’ on one side and imprint ‘MEM’ on the other side.
The 20 mg film-coated tablets are pale red to grey-red, oval-oblong
film-coated tablets with imprint ‘20’
on one side and imprint ‘MEM’ on the other side.
Axura 20 mg film-coated tablets
Pale red to grey-red,
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 26-02-2024
Karakteristik produk Karakteristik produk Bulgar 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Bulgar 05-01-2012
Selebaran informasi Selebaran informasi Spanyol 26-02-2024
Karakteristik produk Karakteristik produk Spanyol 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Spanyol 05-01-2012
Selebaran informasi Selebaran informasi Cheska 26-02-2024
Karakteristik produk Karakteristik produk Cheska 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Cheska 05-01-2012
Selebaran informasi Selebaran informasi Dansk 26-02-2024
Karakteristik produk Karakteristik produk Dansk 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Dansk 05-01-2012
Selebaran informasi Selebaran informasi Jerman 26-02-2024
Karakteristik produk Karakteristik produk Jerman 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Jerman 05-01-2012
Selebaran informasi Selebaran informasi Esti 26-02-2024
Karakteristik produk Karakteristik produk Esti 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Esti 05-01-2012
Selebaran informasi Selebaran informasi Yunani 26-02-2024
Karakteristik produk Karakteristik produk Yunani 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Yunani 05-01-2012
Selebaran informasi Selebaran informasi Prancis 26-02-2024
Karakteristik produk Karakteristik produk Prancis 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Prancis 05-01-2012
Selebaran informasi Selebaran informasi Italia 26-02-2024
Karakteristik produk Karakteristik produk Italia 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Italia 05-01-2012
Selebaran informasi Selebaran informasi Latvi 26-02-2024
Karakteristik produk Karakteristik produk Latvi 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Latvi 05-01-2012
Selebaran informasi Selebaran informasi Lituavi 26-02-2024
Karakteristik produk Karakteristik produk Lituavi 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Lituavi 05-01-2012
Selebaran informasi Selebaran informasi Hungaria 26-02-2024
Karakteristik produk Karakteristik produk Hungaria 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Hungaria 05-01-2012
Selebaran informasi Selebaran informasi Malta 26-02-2024
Karakteristik produk Karakteristik produk Malta 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Malta 05-01-2012
Selebaran informasi Selebaran informasi Belanda 26-02-2024
Karakteristik produk Karakteristik produk Belanda 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Belanda 05-01-2012
Selebaran informasi Selebaran informasi Polski 26-02-2024
Karakteristik produk Karakteristik produk Polski 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Polski 05-01-2012
Selebaran informasi Selebaran informasi Portugis 26-02-2024
Karakteristik produk Karakteristik produk Portugis 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Portugis 05-01-2012
Selebaran informasi Selebaran informasi Rumania 26-02-2024
Karakteristik produk Karakteristik produk Rumania 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Rumania 05-01-2012
Selebaran informasi Selebaran informasi Slovak 26-02-2024
Karakteristik produk Karakteristik produk Slovak 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Slovak 05-01-2012
Selebaran informasi Selebaran informasi Sloven 26-02-2024
Karakteristik produk Karakteristik produk Sloven 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Sloven 05-01-2012
Selebaran informasi Selebaran informasi Suomi 26-02-2024
Karakteristik produk Karakteristik produk Suomi 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Suomi 05-01-2012
Selebaran informasi Selebaran informasi Swedia 26-02-2024
Karakteristik produk Karakteristik produk Swedia 26-02-2024
Laporan Penilaian publik Laporan Penilaian publik Swedia 05-01-2012
Selebaran informasi Selebaran informasi Norwegia 26-02-2024
Karakteristik produk Karakteristik produk Norwegia 26-02-2024
Selebaran informasi Selebaran informasi Islandia 26-02-2024
Karakteristik produk Karakteristik produk Islandia 26-02-2024
Selebaran informasi Selebaran informasi Kroasia 26-02-2024
Karakteristik produk Karakteristik produk Kroasia 26-02-2024

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen